NASDAQ:KURA Kura Oncology Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.50 +0.17 (+0.93%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$17.83▼$19.1850-Day Range$10.71▼$18.5052-Week Range$10.41▼$22.03Volume775,361 shsAverage Volume727,322 shsMarket Capitalization$1.23 billionP/E RatioN/ADividend YieldN/APrice Target$38.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Kura Oncology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside105.4% Upside$38.00 Price TargetShort InterestBearish7.71% of Float Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment1.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.19) to ($2.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.40 out of 5 starsMedical Sector131st out of 1,428 stocksPharmaceutical Preparations Industry52nd out of 682 stocks 3.5 Analyst's Opinion Consensus RatingKura Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.00, Kura Oncology has a forecasted upside of 105.4% from its current price of $18.50.Amount of Analyst CoverageKura Oncology has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.71% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Kura Oncology has recently increased by 10.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kura Oncology is -0.76. Previous Next 3.3 News and Social Media Coverage News SentimentKura Oncology has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kura Oncology this week, compared to 1 article on an average week.Search Interest7 people have searched for KURA on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of Kura Oncology is held by insiders.Percentage Held by Institutions94.65% of the stock of Kura Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kura Oncology are expected to grow in the coming year, from ($2.19) to ($2.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address About Kura Oncology (NASDAQ:KURA) StockKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.Read More KURA Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comKura Oncology (NASDAQ:KURA) Stock Price Up 2.9%June 30, 2022 | finance.yahoo.comKura Oncology Stock Scores Rising Relative StrengthJune 19, 2022 | americanbankingnews.comReviewing SELLAS Life Sciences Group (NASDAQ:SLS) & Kura Oncology (NASDAQ:KURA)June 15, 2022 | americanbankingnews.comKura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of "Buy" from BrokeragesMay 4, 2022 | seekingalpha.comKura Oncology Q1 2022 Earnings PreviewMay 4, 2022 | seekingalpha.comKura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2022 Results - Earnings Call TranscriptMay 4, 2022 | finance.yahoo.comKura Oncology Reports First Quarter 2022 Financial ResultsApril 27, 2022 | finance.yahoo.comKura Oncology to Report First Quarter 2022 Financial ResultsApril 8, 2022 | finance.yahoo.comKura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung CancerMarch 11, 2022 | morningstar.comKura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting | MorningstarMarch 11, 2022 | benzinga.comAdagene, Kura Oncology, Cullinan Oncology Announce Presentations At AACR 2022March 8, 2022 | finance.yahoo.comKura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual MeetingFebruary 25, 2022 | benzinga.comCredit Suisse Maintains Outperform on Kura Oncology, Raises Price Target to $27February 24, 2022 | benzinga.comKura Oncology: Q4 Earnings InsightsFebruary 24, 2022 | apnews.comKura Oncology: Q4 Earnings SnapshotFebruary 24, 2022 | finance.yahoo.comKura Oncology Reports Fourth Quarter and Full Year 2021 Financial ResultsFebruary 23, 2022 | seekingalpha.comKura Oncology Q4 2021 Earnings PreviewFebruary 17, 2022 | finance.yahoo.comKura Oncology to Report Fourth Quarter and Full Year 2021 Financial ResultsFebruary 15, 2022 | benzinga.comJefferies Initiates Coverage On Kura Oncology with Buy Rating, Announces Price Target of $35February 10, 2022 | benzinga.comKura Oncology to Participate in SVB Leerink Global Healthcare ConferenceFebruary 7, 2022 | finance.yahoo.comWe're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn RateFebruary 6, 2022 | finance.yahoo.comDid The Smart Money Play Kura Oncology, Inc. (KURA) Correctly?February 1, 2022 | seekingalpha.comKura Oncology CFO Marc Grasso to step downFebruary 1, 2022 | finance.yahoo.comKura Oncology Expands Leadership Team with Key PromotionsJanuary 21, 2022 | benzinga.comKura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer StudySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KURA CUSIPN/A CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees121Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today7/03/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$38.00 High Stock Price Forecast$80.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside+105.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.990010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130.47 million Net MarginsN/A Pretax MarginN/A Return on Equity-25.49% Return on Assets-24.28% Debt Debt-to-Equity RatioN/A Current Ratio27.48 Quick Ratio27.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.61 per share Price / Book2.43Miscellaneous Outstanding Shares66,640,000Free Float63,371,000Market Cap$1.23 billion OptionableOptionable Beta1.06 Kura Oncology Frequently Asked Questions Should I buy or sell Kura Oncology stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kura Oncology stock. View analyst ratings for Kura Oncology or view top-rated stocks. What is Kura Oncology's stock price forecast for 2022? 6 Wall Street research analysts have issued 1-year price targets for Kura Oncology's shares. Their KURA stock forecasts range from $26.00 to $80.00. On average, they anticipate Kura Oncology's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 105.4% from the stock's current price. View analysts' price targets for Kura Oncology or view top-rated stocks among Wall Street analysts. How has Kura Oncology's stock price performed in 2022? Kura Oncology's stock was trading at $14.00 on January 1st, 2022. Since then, KURA shares have increased by 32.1% and is now trading at $18.50. View the best growth stocks for 2022 here. When is Kura Oncology's next earnings date? Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Kura Oncology. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) issued its earnings results on Wednesday, May, 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.03. During the same period in the previous year, the business posted ($0.46) earnings per share. View Kura Oncology's earnings history. Who are Kura Oncology's key executives? Kura Oncology's management team includes the following people: Dr. Troy Edward Wilson J.D., Ph.D., Chairman, CEO, Pres & Principal Financial Officer (Age 53, Pay $984.61k)Ms. Kathleen Ford, Chief Operating Officer (Age 75, Pay $689.32k)Dr. Marc Grasso M.D., Advisor (Age 48, Pay $651.68k)Ms. Kirsten Flowers, Chief Commercial Officer (Age 47, Pay $642.98k)Dr. Stephen Dale M.D., Chief Medical Officer (Age 50, Pay $811.58k)Mr. Thomas Doyle, Principal Accounting Officer & Sr. VP of Fin. and Accounting (Age 51)Mr. Pete De Spain, Sr. VP of Investor Relations & Corp. CommunicationsMs. Teresa Brophy Bair Esq., J.D., Chief Legal Officer & Corp. Sec. (Age 51)Mr. James E. Basta J.D., Esq., Chief Compliance Officer & Corp. Sec. (Age 56)Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing Who are some of Kura Oncology's key competitors? Some companies that are related to Kura Oncology include Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Mirati Therapeutics (MRTX), Cerevel Therapeutics (CERE), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY) and AbCellera Biologics (ABCL). View all of KURA's competitors. What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD). What is Kura Oncology's stock symbol? Kura Oncology trades on the NASDAQ under the ticker symbol "KURA." How do I buy shares of Kura Oncology? Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kura Oncology's stock price today? One share of KURA stock can currently be purchased for approximately $18.50. How much money does Kura Oncology make? Kura Oncology (NASDAQ:KURA) has a market capitalization of $1.23 billion. The company earns $-130.47 million in net income (profit) each year or ($1.990010) on an earnings per share basis. How many employees does Kura Oncology have? Kura Oncology employs 121 workers across the globe. How can I contact Kura Oncology? Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for Kura Oncology is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com. This page (NASDAQ:KURA) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
